Portal de Periódicos da CAPES

COVID-19 Vaccination Coverage Among Adolescents Aged 12–17 Years — United States, December 14, 2020–July 31, 2021

2021; Centers for Disease Control and Prevention; Volume: 70; Issue: 35 Linguagem: Inglês

10.15585/mmwr.mm7035e1

1545-861X

Bhavini Patel Murthy, Elizabeth R. Zell, Ryan Saelee, Neil Murthy, Lu Meng, Seth Meador, Kirsten Reed, Lauren Shaw, Lynn Gibbs‐Scharf, A. D. McNaghten, Anita Patel, Shannon Stokley, Stephen A. Flores, Jonathan S. Yoder, Carla L. Black, LaTreace Harris,

SARS-CoV-2 and COVID-19 Research

Receipt of ≥1 COVID-19 vaccine dose is defined as having received either ≥1 of the 2 Pfizer-BioNTech or Moderna vaccine doses, or a single dose of the Janssen (Johnson & Johnson) vaccine.As of August 17, 2021, only the Pfizer-BioNTech vaccine had been authorized for use among adolescents aged 12-17 years.Moderna and Janssen COVID-19 vaccines were not authorized under emergency use for this age group during December 14, 2020-July 31, 2021.However, doses of these vaccines administered to persons aged 12-17 years were included in this analysis.During February 27, 2021-July 31, 2021, a total of 21,919 adolescents aged 12-17 years were reported to have received 1 dose of the Janssen COVID-19 vaccine.During December 14, 2021-July 31, 2021, a total of 27,226 adolescents aged 12-17 years were reported to have received only the first dose of the Moderna COVID-19 vaccine; 66,032 adolescents aged 12-17 years were reported to have received both doses of the Moderna COVID-19 vaccine; 2,190 were reported to have received Pfizer-BioNTech for the first dose but Moderna for the second dose; and 5,726 were reported to receive Moderna for the first dose but Pfizer-BioNTech for the second dose.† Series completion was defined as receipt of either both doses of the Pfizer-BioNTech or Moderna vaccines, including those that might have received mismatched products between the first and second dose (i.e., Pfizer-BioNTech for the first dose and Moderna for the second dose or vice versa) or a single dose of the Janssen vaccine.[Mississippi] to 60.3% [Vermont]).By age group, 36.0%,40.9%, and 50.6% of adolescents aged 12-13, 14-15, and 16-17 years, respectively, received ≥1 dose; 25.4%, 30.5%, and 40.3%, respectively, completed the vaccine series.Improving vaccination coverage and implementing COVID-19 prevention strategies are crucial to reduce COVID-19-associated morbidity and mortality among adolescents and to facilitate safer reopening of schools for in-person learning.Data on COVID-19 vaccine administration in the United States are reported to CDC by jurisdictions, pharmacies, and federal entities through immunization information systems (IISs), § the Vaccine Administration Management System (VAMS), ¶ or direct data submission.**Adolescents aged 12-17 years with valid residence in one of 49 states or DC who received ≥1 dose of a COVID-19 vaccine during December 14, 2020-July 31, 2021, and whose data were reported to CDC by August 11, 2021, were included in this analysis.† † COVID-19 vaccine doses administered to persons residing in Idaho were excluded because the state has datasharing restrictions on information reported to CDC.Receipt of ≥1 COVID-19 vaccine dose and series completion among adolescents aged 12-17 years was calculated overall and stratified by age (12-13, 14-15, and 16-17 years), sex, and jurisdiction (49 states and DC).As of August 17, 2021, only the Pfizer-BioNTech vaccine had been authorized for use among adolescents aged 12-17 years in the United States.Moderna and Janssen (Johnson & Johnson) COVID-19 vaccines were not authorized under emergency use for this age group during the analysis period; however, for reasons that are § IISs are confidential, computerized, population-based systems that collect and consolidate vaccination data from providers in 64 public health jurisdictions and can be used to track administered vaccines and measure vaccination coverage.The 64 IIS jurisdictions comprise the 50 U.S. states, eight U.S.